Carbamazepine
Carbamazepine (Tegretol) treats epilepsy and trigeminal nerve pain and is also used for bipolar disorder. Two immune-system gene variants raise the risk of severe skin reactions to it: HLA-B*15:02, strongly linked to Stevens-Johnson syndrome and toxic epidermal necrolysis, and HLA-A*31:01, linked to a wider range of reactions. CPIC recommends that people who have not taken carbamazepine before avoid it if they carry HLA-B*15:02, or carry HLA-A*31:01 and have other options [1]. Gene2Rx does not test HLA genes, so a Gene2Rx report cannot answer this question.
| Brand names | Tegretol, Tegretol-XR |
|---|---|
| Used for | Epilepsy, trigeminal neuralgia; bipolar disorder |
| Genes | HLA-B (HLA-B*15:02), HLA-A (HLA-A*31:01) |
| Guidance | CPIC guideline (2017 update) [1]; FDA label (boxed warning and Warnings) [2] |
| Gene2Rx coverage | Not tested. Gene2Rx does not call HLA genes from any uploaded data. |
How carbamazepine works
Carbamazepine blocks sodium channels in nerve cells in a way that depends on how often they fire, which stops the rapid repeated firing behind seizures. CPIC notes FDA approval for epilepsy, trigeminal neuralgia and bipolar disorder [1]; the Tegretol label covers epilepsy and trigeminal neuralgia [2].
The liver enzyme CYP3A4 converts carbamazepine to carbamazepine-10,11-epoxide, a metabolite with anticonvulsant activity in animal studies, and epoxide hydrolase then clears the epoxide. Carbamazepine speeds up its own metabolism: over 3 to 5 weeks its half-life falls from 25 to 65 hours at first to 12 to 17 hours. Drugs that block CYP3A4, such as clarithromycin, erythromycin, fluconazole, diltiazem, verapamil and grapefruit juice, can raise carbamazepine levels, and enzyme inducers can lower them [2]. No guideline uses a CYP genotype to dose carbamazepine; the genetic guidance concerns HLA and skin reactions only.
How HLA-B*15:02 and HLA-A*31:01 affect carbamazepine
HLA-B and HLA-A make cell-surface molecules that show protein fragments to the immune system. They are among the most variable genes in the genome, with more than 4,000 HLA-B and 3,000 HLA-A alleles known. Particular alleles can let a drug set off an immune attack, here led by cytotoxic T cells against the skin. Results are reported as positive (one or two copies) or negative; there is no intermediate result [1].
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the same blistering reaction at different extents, with skin detachment over up to 10% of the body in SJS and more than 30% in TEN. Mortality is typically below 5% for SJS and can exceed 30% for TEN [1]. The label estimates SJS/TEN at 1 to 6 per 10,000 new carbamazepine users in countries with mainly European-ancestry populations, and about 10 times higher in some Asian countries [2].
HLA-B*15:02 is most common in East Asian (6.9%), Oceanian (5.4%) and South or Central Asian (4.6%) populations, but less common in Japanese (below 1%) and Korean (below 2.5%) populations and rare (below 1%) in most other groups. In Han Chinese patients, testing for it had an estimated sensitivity of 98% and a negative predictive value of 100% for carbamazepine SJS/TEN, but a positive predictive value of 7.7%: most carriers who take carbamazepine do not develop SJS/TEN. Ancestry is not a reliable substitute for the test; in one European study, 4 of 12 people with SJS/TEN carried HLA-B*15:02 and were later found to have some Southeast Asian ancestry [1].
HLA-A*31:01 is associated with milder rashes (maculopapular exanthema), with drug reaction with eosinophilia and systemic symptoms (DRESS), and with SJS/TEN. Its frequency is about 3% in European and 6% in Hispanic or South American populations, 8% in Japanese and 5% in South Korean populations. In European populations, CPIC estimates a positive predictive value of 43% for all carbamazepine hypersensitivity reactions combined, with 47 people needing testing to prevent one reaction [1].
What the guidelines recommend
CPIC's 2017 update kept its original HLA-B*15:02 recommendations, added HLA-A*31:01 for carbamazepine and extended the HLA-B*15:02 advice to oxcarbazepine. The recommendations apply whatever a person's region of origin or ethnic group, and to children as well as adults. If only one allele was tested, CPIC says to assume the other is negative [1].
| Result | What it means | Guideline recommendation (CPIC) |
|---|---|---|
| Both negative | Normal risk of SJS/TEN, DRESS and rash. | Use carbamazepine per standard dosing (strong). |
| HLA-B*15:02 positive (any HLA-A*31:01 result) | Greater risk of SJS/TEN. | If carbamazepine-naive, do not use it (strong). If taken consistently for more than 3 months without a skin reaction, cautiously consider it (optional). |
| HLA-A*31:01 positive, HLA-B*15:02 negative | Greater risk of SJS/TEN, DRESS and rash. | If carbamazepine-naive and alternatives are available, do not use it (strong). If no alternative, consider it with more frequent monitoring and stop at the first sign of a skin reaction (optional). If taken for more than 3 months without a reaction, cautiously consider it (optional). |
The 3-month cut-off reflects timing: with regular dosing, SJS/TEN usually appears within 4 to 28 days, and reactions generally occur within the first 3 months [1]. The FDA label's boxed warning says patients with ancestry in genetically at-risk populations should be screened for HLA-B*15:02 before starting carbamazepine, and that those who test positive should not be treated unless the benefit clearly outweighs the risk. For HLA-A*31:01 it asks prescribers to weigh risks and benefits, and it stresses that genotyping never replaces clinical vigilance [2]. The FDA's Table of Pharmacogenetic Associations summarizes both entries [3].
Getting tested
HLA-B*15:02 and HLA-A*31:01 are checked with a clinical HLA genotyping test ordered by a prescriber, ideally before the first dose. The label recommends HLA-B*15:02 testing for people with ancestry in populations where the allele may be present, noting that ancestry is hard to pin down and often mixed [2]; CPIC's recommendations apply to any result, whatever the person's ancestry [1]. If you already have a result from a clinical lab, bring it to the appointment.
A negative result is not a guarantee. Carbamazepine can cause serious skin reactions in people without either allele, and the label lists other serious risks such as blood disorders. Contact your prescriber at once about a new rash, blistering, mouth sores or fever in the first months of treatment. Do not stop an anticonvulsant suddenly or on your own: the label warns that abrupt discontinuation risks severe seizures [2], so any change should go through your prescriber.
What a Gene2Rx report cannot tell you
Gene2Rx does not call HLA genes, from consumer DNA tests or from whole-genome sequencing. A Gene2Rx report therefore contains no HLA-B*15:02 or HLA-A*31:01 result and gives no carbamazepine recommendation. Nothing else in the report, including CYP3A4 or other gene results, can be read as clearing you for carbamazepine. The guideline answer requires a clinical HLA test.
Common questions
I am not of Asian ancestry. Does HLA testing matter for me?
HLA-B*15:02 is uncommon outside Asian and Oceanian populations, but HLA-A*31:01 occurs in about 3% of European and 6% of Hispanic or South American populations, and mixed ancestry is common [1]. Whether to test is a decision for your prescriber.
Does HLA-B*15:02 matter for other seizure medicines?
CPIC applies the same HLA-B*15:02 advice to oxcarbazepine, and HLA-B*15:02 has also been linked to SJS/TEN with phenytoin. For other aromatic anticonvulsants the evidence is weaker, so CPIC advises caution in choosing an alternative rather than a firm rule [1].
I have taken carbamazepine for years. Should I be tested now?
CPIC considers people who have taken it continuously for more than 3 months without a skin reaction to be at extremely low, though not zero, risk of a future reaction, regardless of HLA-B*15:02 status [1]. Discuss it with your prescriber before any change.
Sources and further reading
- Phillips EJ et al. Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharmacol Ther (2018). HLA background, allele frequencies, predictive values, SJS/TEN, DRESS, recommendations.
- Tegretol and Tegretol-XR (carbamazepine): prescribing information (Novartis). DailyMed. Boxed warning on SJS/TEN and HLA-B*15:02, HLA-A*31:01 warning, metabolism, interactions.
- US Food and Drug Administration. Table of Pharmacogenetic Associations. HLA-B*15:02 and HLA-A*31:01 entries for carbamazepine.
Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.
I'm Interested